

Global phase 2 studies of precision medicine based c-MET inhibitor ABN401

Abion Inc.



ONCOLOGY	Phase 2
Product Type	Small molecule inhibitor
Indication	NSCLC, MET Exon 14 skipping
Target	c-MET
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • ABN401 is an anticancer targets c-MET • c-MET is a signaling Protein Tyrosine Kinase and functions for cell growth in normal cell. But when mutated, it triggers the proliferation and metastasis in cancer, abundantly in NSCLC. • ABN401, a highly selective and potent c-MET kinase inhibitor, specifically targets only c-MET • ABN401 effectively inhibits c-MET signaling by binding to its intracellular catalytic domain, blocking downstream signaling, regardless of HGF dependence
Competitiveness	<ul style="list-style-type: none"> • Superior safety/efficacy profile compared to other competitive c-MET drugs • 99% target specificity, outstanding selectivity compared to other c Met TKIs under development • Low affinity for blood albumin increases safety profile and lowers the risk of adverse events
Development Stage	Phase 2
Route of Administration	Oral Administration